Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Macular Degeneration
Interventions: Not listed
Lead sponsor: ORA, Inc.; Industry
Eligibility: 20 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Age Related Macular Degeneration (AMD)
Interventions: Health Management Tool (HMT); Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 23
States / cities: Beverly Hills, California • Sacramento, California • Torrance, California + 20 more

Conditions: Ischemic Central Retinal Vein Occlusion
Interventions: Ranibizumab (Lucentis); Drug
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Retinal Degeneration, Retinitis Pigmentosa, Eye Diseases, Hereditary
Interventions: Not listed
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 8 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Durham, North Carolina

Conditions: Diabetic Retinopathy
Interventions: ruboxistaurin, placebo; Drug
Lead sponsor: Chromaderm, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 36
States / cities: Artesia, California • Palm Springs, California • Poway, California + 33 more

Conditions: Diabetic Retinopathy
Interventions: handheld fundus camera; Device
Lead sponsor: Digital Diagnostics, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 9
States / cities: Norco, California • Pomona, California • Jacksonville, Florida + 6 more

Conditions: Inherited Retinal Diseases
Interventions: Low Vision Rehabilitation (LVR), Emotion Regulation Therapy (ERT); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Retinal Vein Occlusion
Interventions: Minocycline, Placebo, Bevacizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Genotype, Retinal Disease
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: Fluocinolone Acetonide; Drug
Lead sponsor: Alimera Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 3
States / cities: Lexington, Kentucky • Boston, Massachusetts • Cleveland, Ohio

Conditions: A History of Radiation Therapy for a Tumor in the Vicinity of the Retina(s)
Interventions: Not listed
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Retinitis Pigmentosa
Interventions: Ultrasound Stimulus; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions: QR-421a, Sham-procedure; Drug · Other
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 12 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Age-Related (Dry) Macular Degeneration
Interventions: AC Tap (anterior chamber paracenthesis); Procedure
Lead sponsor: ClinOmicsAI; Network
Eligibility: 50 Years to 89 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Erie, Pennsylvania

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Foscarnet sodium; Drug
Lead sponsor: Astra USA; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: Beverly Hills, California • Los Angeles, California • Redwood City, California + 7 more

Conditions: Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions: Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention; Drug · Other
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 8 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 7 more

Conditions: Age-Related Macular Degeneration
Interventions: Ranibizumab (Lucentis), 0.5mg ranibizumab; Drug
Lead sponsor: David M. Brown, M.D.; Other
Eligibility: 55 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypotony Ocular, Cornea Folds and Rupture of Bowman's Membrane Both Eyes, Maculopathy
Interventions: Ophthalmic imaging; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Retinal Vein Occlusion, Diabetic Macular Edema
Interventions: KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0% Ophthalmic Suspension; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: Beverly Hills, California • Boston, Massachusetts

Conditions: Geographic Atrophy
Interventions: Pegcetacoplan, Sham Procedure; Drug · Other
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 35
States / cities: Mobile, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more

Conditions: Age-related Macular Degeneration, Age-related Maculopathy
Interventions: Observational-1, Observational-2; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 49 Years and older
Enrollment: 603 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Pittsburgh, Pennsylvania

Conditions: Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions: Gene Therapy Product-MCO-010, Sham Injection; Biological · Procedure
Lead sponsor: Nanoscope Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more

Conditions: Epiretinal Membrane, Macular Edema
Interventions: Dexamethasone Intravitreal Implant; Drug
Lead sponsor: Barnes Retina Institute; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Chesterfield, Missouri • St Louis, Missouri

Search by objective public record fields.

A Single-Center Pilot Study to Assess Macular Function

A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)

Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion

Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

Camera Qualification Study

Optimizing Low Vision Rehabilitation in Emotionally Distressed Patients With Inherited Retinal Diseases

Minocycline to Treat Central Retinal Vein Occlusion

Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

Retinal Oxygen Function After Radiation Therapy

Evoked Retinal Response

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

Ocular Proteomics Testing In Chronic Atrophy

A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

Anterior Corneal Striae in Hypotony

Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema

Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy

GARM II: A Study on the Genetics of Age-related Maculopathy

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane